Abstract
Abstract
Background
Human babesiosis is a worldwide disease caused by intraerythrocytic protozoa of the genus Babesia. It is transmitted by bites from ixodid ticks, and mechanically transmitted by blood transfusion. It is primarily treated with quinine and/or atovaquone, which are not readily available in China. In this study, we developed a novel treatment regimen involving doxycycline monotherapy in a patient with severe Babesia venatorum infection as an alternative therapeutic medication. The aim of our study is to provide a guidance for clinical practice treatment of human babesiosis.
Case presentation
A 73-year-old man who had undergone splenectomy and blood transfusion 8 years prior, presented with an unexplained fever, headache, and thrombocytopenia, and was admitted to the Fifth Medical Center of the PLA General Hospital. He was diagnosed with B. venatorum infection by morphological review of thin peripheral blood smears, which was confirmed by multi-gene polymerase chain reaction (PCR), and sequencing of the entire 18s rRNA and partial β-tubulin encoding genes, as well as isolation by animal inoculation. The doxycycline monotherapy regimen (peros, 0.1 g bisindie) was administered following pharmacological guidance and an effective outcome was observed. The patient recovered rapidly following the doxycycline monotherapy. The protozoan load in peripheral blood samples decreased by 88% in hematocrit counts after 8 days, and negative PCR results were obtained after 90 days of follow-up at the hospital. The treatment lasted for 3 months without any side effects or sequelae. The nine-month follow-up survey of the patient did not reveal any signs of recrudescence or anti-babesial tolerance.
Conclusions
We have reported a clinical case of successful doxycycline monotherapy for human babesiosis caused by B. venatorum, which provides an optional medical intervention for human babesiosis.
Graphical Abstract
Funder
State Key Research Development Program of China
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Medicine
Reference40 articles.
1. Vannier E, Krause PJ. Human babesiosis. N Engl J Med. 2012;366(25):2397–407.
2. Krause PJ, Auwaerter PG, Bannuru RR, Branda JA, Falck-Ytter YT, Lantos PM, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on diagnosis and management of Babesiosis. Clin Infect Dis. 2021;72(2):e49–e64.
3. Gray JS, Estrada-Pena A, Zintl A. Vectors of babesiosis. Annu Rev Entomol. 2019;64:149–65.
4. Gray EB, Herwaldt BL. Babesiosis surveillance—United States, 2011–2015. MMWR Surveill Summ. 2019;68(6):1–11.
5. Xin CM, Bo XJ, Lin A, Peng S, Peng S, Xu CJ. Epidemic status and research progress of babesiosis in China. J Trop Dis Parasitol. 2022;20(3):149–57. (in Chinese).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献